Vasileios Assikis, MD
Hematology & Oncology · Newnan, GANPI 1730147596
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 17.7%. Reporting peaked in 2021 at $16,399 and has fallen 88.1% since, to $1,959 in 2025. Among hematology & oncology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $178.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myovant Sciences Inc.$11K
- AstraZeneca$11K
- Pfizer$8K
- Gilead$7K
- Johnson & Johnson$6K
- Exelixis Inc.$3K
- plus $16K from 47 others
Across 643 payments — averaging $4804.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.6M
- Daiichi Sankyo Inc.$340K
- Exelixis Inc.$220K
- AstraZeneca$195K
- EMD Serono, Inc.$182K
- Bayer$179K
- plus $397K from 9 others
What the payments were for
- Consulting fees$21,64635%
- Speaking & faculty fees$29,20047%
- Travel & lodging$3,5746%
- Food & beverage$6,54411%
- Education$7381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,701 in reported general payments places this provider in the 90th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 144 | $1,619,713 |
| ErleadaApalutamide | 119 | $1,594,515 |
| RevlimidLenalidomide | 85 | $1,385,176 |
| NubeqaDarolutamide | 82 | $987,883 |
| Lupron DepotLeuprolide Acetate | 134 | $807,814 |
| CabometyxCabozantinib S-Malate | 25 | $731,351 |
| BrukinsaZanubrutinib | 46 | $607,693 |
| Abiraterone Acetate | 284 | $570,254 |
| VerzenioAbemaciclib | 33 | $376,172 |
| IbrancePalbociclib | 26 | $352,924 |
| LenvimaLenvatinib Mesylate | 11 | $260,070 |
| JaypircaPirtobrutinib | 12 | $257,200 |
| Udenyca AutoinjectorPegfilgrastim-Cbqv | 58 | $235,650 |
| ImbruvicaIbrutinib | 13 | $207,333 |
| CalquenceAcalabrutinib Maleate | 12 | $184,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $196 | $1,619,713144 claims |
| Johnson & JohnsonErleada, Xarelto | $5,803 | $1,606,571133 claims |
| Bristol Myers SquibbRevlimid | $66 | $1,385,17685 claims |
| BayerNubeqa | $2,988 | $987,88382 claims |
| AbbVieLupron Depot | $525 | $807,814134 claims |
| Exelixis Inc.Cabometyx | $3,288 | $731,35125 claims |
| Lilly USA, LLCVerzenio, Jaypirca | $31 | $633,37245 claims |
| Beigene USA, Inc.Brukinsa | $1,467 | $607,69346 claims |
| PfizerIbrance, Eliquis | $7,621 | $424,443135 claims |
| Eisai Inc.Lenvima | $3,102 | $260,07011 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $78 | $207,33313 claims |
| AstraZenecaCalquence | $10,756 | $184,84112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Newnan
- Bamidele AdesunloyeNewnan$38K
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
- Chandar BhimaniConyers$483K
- Ticiana LealAtlanta$450K
- Steven McCuneMarietta$450K
- Jorge LeguizamoLawrenceville$409K
- Trevor FeinsteinFayetteville$341K
- Jigarkumar ParikhAugusta$267K
- Ajay NookaAtlanta$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.